Beyond the weight-loss supercycle, a new class of targeted therapies is driving institutional rotation into mid-cap biotech – and the valuation entry points remain compelling.
Why IonQ Is Emerging as the Stock to Watch in the Next Phase of Computational Power
May 30, 2026 AI needs buildings, not just chips Why Comfort Systems (FIX) keeps getting pulled along by data center…
Mounjaro up 125%. Zepbound up 79%. A new oral pill just launched. The growth story keeps widening.
49% revenue growth. 84 million active buyers. A fintech arm expanding at 87%. The opportunity is hiding in plain sight.
May 29, 2026 SpaceX + Tesla: The Merger Nobody Can Quite Price Featured: SpaceX + Tesla: The Merger Nobody Can…
85% revenue growth. $1.63B in Q1. A Rule of 40 score of 145%. The question now is whether the multiple makes sense — or has already been answered.
A single analyst call rewired how Wall Street thinks about memory chips — and MU hasn’t looked back.
NVDA beat hard, guided higher, and still slipped. The market’s reaction might be the most important signal of the quarter.
A landmark CHIPS Act deal and a commercial hardware breakthrough are changing the conversation around this volatile pure-play.
